Home

This technology uses drugs that stabilize β-catenin to boost protective immune cells in the lungs, reducing damage from pulmonary hemorrhage and inflammatory lung diseases by activating a novel immunomodulatory pathway. Background:
Pulmonary hemorrhage and other inflammatory lung diseases represent significant clinical challenges due to their high morbidity and mortality rates. These conditions are characterized by excessive inflammation and immune dysregulation within the lung tissue, leading to tissue damage, impaired gas exchange, and life-threatening complications. Current therapeutic strategies primarily focus on symptomatic management, such as corticosteroids and supportive care, but these approaches often fail to address the underlying immune mechanisms driving disease progression. As a result, there is a pressing need for innovative therapies that can modulate the immune response more precisely, reduce inflammation, and promote tissue repair, thereby improving outcomes for patients affected by these severe pulmonary conditions. Despite ongoing research, existing treatments for inflammatory lung diseases and pulmonary hemorrhage remain inadequate. Corticosteroids and broad-spectrum immunosuppressants, while effective at dampening inflammation, carry significant risks of systemic side effects and increased susceptibility to infections. Moreover, these therapies do not selectively target the specific immune pathways implicated in lung injury, leading to suboptimal efficacy and frequent relapses. Attempts to modulate regulatory T cell (Treg) populations have been limited by challenges in achieving tissue specificity and sustained functional enhancement. Consequently, there is a critical gap in the development of targeted immunomodulatory therapies that can provide durable protection against lung inflammation and hemorrhage without compromising overall immune competence.Technology Overview:  
This technology utilizes β-catenin agonists to pharmacologically stabilize β-catenin, offering a novel therapeutic approach for protecting against pulmonary hemorrhage and other inflammatory lung diseases. The treatment works by inducing a specialized phenotype in tissue-resident regulatory T cells (Tregs) within the lung. In preclinical studies using a mouse model of lung injury, administration of β-catenin agonists led to increased lung Treg populations and significantly reduced lung damage, as evidenced by pathology and histological analysis. This method demonstrates the potential for a targeted, immune-based intervention in the management of inflammatory lung conditions, with applications for clinicians, pharmaceutical developers, and researchers in immunology and pulmonary medicine. What differentiates this technology is its ability to pharmacologically mimic the protective effects seen in genetic models of β-catenin stabilization, offering a practical and scalable therapeutic strategy. Unlike conventional anti-inflammatory treatments that broadly suppress immune responses, this approach specifically enhances a beneficial immunoregulatory pathway thereby promoting tissue protection without compromising overall immune function. The elucidation of this pathway provides a unique target for drug development, setting the technology apart from existing therapies by focusing on the modulation of tissue-resident Tregs and their role in lung repair. This targeted mechanism not only addresses a critical unmet need in pulmonary hemorrhage treatment but also opens avenues for broader applications in inflammatory disease management. https://suny.technologypublisher.com/files/sites/adobestock_282277137.jpegAdvantages:  
•    Provides pharmacological protection against pulmonary hemorrhage and inflammatory lung diseases.
•    Induces a specialized tissue-resident regulatory T cell (Treg) phenotype to modulate immune response.
•    Recapitulates protective effects observed in genetic β-catenin stabilization models without genetic modification.
•    Demonstrated efficacy in preclinical mouse models with significant reduction of lung damage.
•    Potentially applicable to broader inflammatory disease management beyond pulmonary conditions.
•    Offers a new therapeutic approach for clinicians and pharmaceutical developers targeting lung inflammation. Applications:  
•    Pulmonary hemorrhage therapeutic development
•    Inflammatory lung disease treatment
•    Immunomodulatory drug discovery
•    Acute lung injury intervention Intellectual Property Summary:
Patent application 63/922,548 filed on 11/21/2025Stage of Development:  
TRL 3. The technology is currently at a preclinical development stage, with proof of concept demonstrated through pharmacologic β-catenin stabilization and validation in relevant in vitro and in vivo lung injury modelsLicensing Status:
This technology is available for licensing.
 

This technology is a computer vision-based software platform that enables real-time human movement analysis, providing physical therapists and trainers with objective feedback and progress tracking through a standard webcam. Background:
Traditional physical therapy and fitness training often rely on subjective visual assessments, which can limit the accuracy and consistency of movement analysis. Recognizing this challenge, the invention was developed to introduce an objective, data-driven solution that enhances motor learning and rehabilitation outcomes by leveraging advancements in computer vision and pose estimation technologies.Technology Overview:  
This innovative software platform uses computer vision algorithms to analyze human movement in real time via a standard webcam. At its core, the system employs advanced pose estimation techniques, such as those found in open-source libraries like MediaPipe, to track joint angles and assess the quality of movements. By integrating theories of motor control and motor learning, the platform delivers precise feedback designed to optimize movement retraining, crucial for both rehabilitation and fitness improvement. The technology features automated repetition counting, detailed feedback on individual performance, and comprehensive summaries after each session, enabling users and professionals to monitor progress effectively. It supports use in both clinical environments and remote settings, offering accessibility and flexibility to a broad range of users. The platform's architecture primarily consists of newly developed code complemented by established video processing tools like OpenCV, ensuring robust performance and accuracy. Designed to address significant gaps in current physical therapy and fitness markets, this solution transforms subjective observations into actionable, evidence-based insights. Future enhancements include cloud-based scaling options and compatibility with health record systems and wearable devices, extending its applicability and integration within modern healthcare ecosystems. https://suny.technologypublisher.com/files/sites/adobestock_1666031996.jpegAdvantages:  
•    Provides objective and precise movement analysis compared to subjective visual assessments.
•    Real-time feedback facilitates immediate correction and more effective motor learning.
•    Uses accessible hardware—a standard webcam—allowing broad adoption without specialized equipment.
•    Supports both clinical and remote use cases, enhancing flexibility and convenience.
•    Automated features such as repetition counting reduce manual tracking efforts.
•    Comprehensive post-session data assists in monitoring long-term progress and rehabilitation outcomes.
•    Incorporates scientifically grounded motor control theories to optimize movement retraining.
•    Future cloud integration promises scalability and seamless interoperability with health technologies. Applications:  
•    Physical therapy clinics for precise movement assessment and rehabilitation monitoring.
•    Fitness training environments where coaches can provide objective, data-driven feedback.
•    Remote rehabilitation programs enabling patients to perform exercises at home with professional oversight.
•    Sports performance analysis to optimize athletes' movement techniques and reduce injury risks.
•    Integration with wearable devices and electronic health records for comprehensive health management.
•    Research settings studying motor control and learning through consistent and repeatable movement data. Intellectual Property Summary:
Copyright, patents availableStage of Development:
TRL 6Licensing Status:
This technology is available for licensing.

This device uses ultrasonic vibrations delivered through a specialized wire to safely and efficiently clear blockages or remove implants from medical tubes, offering a non-invasive, customizable solution for maintaining and treating tube obstructions in healthcare settings. Background:
Nephrostomy tubes and other indwelling medical devices are critical for managing renal obstructions and maintaining urinary drainage in patients with compromised kidney function. However, these tubes are highly susceptible to clogging due to the accumulation of biofilm, mineral deposits, and debris. Such blockages can lead to infection, loss of tube function, and even life-threatening complications if not addressed promptly. Current clinical practice often involves routine tube exchanges, emergency interventions, or flushing procedures to maintain patency, all of which can be uncomfortable for patients, resource-intensive for healthcare systems, and disruptive to patient care. The need for a rapid, effective, and minimally invasive solution to manage and prevent tube occlusion is therefore significant, with the potential to improve patient outcomes and reduce healthcare costs. Existing approaches to clearing clogged nephrostomy tubes and similar devices are fraught with limitations. Flushing and wire probing are frequently ineffective against stubborn obstructions like calcifications or dense biofilms and may require multiple attempts or specialized equipment. Tube exchanges and surgical interventions, while more definitive, are invasive, carry procedural risks, and often necessitate hospital admission or specialized staff, leading to delays in care and increased burden on healthcare resources. Furthermore, these methods do not address the underlying tendency for tubes to re-occlude, resulting in repeated interventions over time. There is a clear unmet need for a solution that can be rapidly deployed at the bedside or in outpatient settings, offering reliable, non-invasive clearance of obstructions without the drawbacks of current techniques.Technology Overview:  
This technology is an ultrasonic transmission system specifically engineered for medical applications such as clearing obstructions from nephrostomy tubes and mobilizing retained implants. The system converts electrical energy into ultrasonic vibrations at adjustable frequencies, paired with an ultrasonic horn and replaceable cavitation wire. The modular design allows for various wire diameters, enabling customization for different clinical scenarios and types of obstructions. What differentiates this solution is its unique integration of modularity, medical-specific enhancements, and procedural flexibility into a single system. Unlike traditional methods that often require invasive procedures, specialized staff, or hospital admission, this device provides a rapid, non-invasive alternative that can be used at the bedside or potentially in home settings. By leveraging commercially available ultrasonic components and introducing novel, application-specific enhancements, the system delivers superior energy transfer and cavitation effects tailored for medical use. This results in reduced hospital resource utilization, extended tube lifespan, and improved patient outcomes, setting it apart from existing solutions in both efficacy and versatility. https://suny.technologypublisher.com/files/sites/adobestock_1641364005.jpegAdvantages:  
•    Non-invasive and rapid clearance of obstructions in medical tubes, reducing the need for surgical interventions.
•    Customizable ultrasonic frequency and power settings for tailored clinical applications.
•    Modular, replaceable cavitation wire with biocompatible materials and surface modifications enhances cavitation and mechanical disruption.
•    Optimized ultrasonic horn design ensures efficient energy transfer and resonance tuning for improved performance.
•    Extends the lifespan of nephrostomy tubes and other medical implants by preventing clogging and biofilm buildup.
•    Enables bedside or potential home use, decreasing hospital admissions and healthcare resource utilization.
•    Adaptable to a variety of medical tubes and retained implants, including ureteral stents and catheters. Applications:  
•    Clearing clogged nephrostomy tubes
•    Removing biofilm from catheters
•    Mobilizing retained ureteral stents
•    Fragmenting urinary tract stones
•    Clearing obstructions in medical drains Intellectual Property Summary:
Patent PendingStage of Development:
TRL 3Licensing Status:
This technology is available for licensing.
 

A specially designed peptide blocks two key enzymes needed for ribosome production in cancer cells, shutting down their protein-making machinery and offering a new, more effective way to treat cancer and prevent drug resistance. Background:
Ribosome biogenesis is a fundamental cellular process involving the coordinated synthesis of ribosomal RNA (rRNA) and transfer RNA (tRNA), which are essential for protein production. In healthy cells, this process is tightly regulated to match physiological needs. However, in cancer cells, ribosome biogenesis is often dramatically upregulated to support the increased demand for protein synthesis required for rapid cell proliferation. This upregulation is driven by heightened activity of RNA Polymerase I (Pol I), which transcribes rRNA, and RNA Polymerase III (Pol III), which transcribes tRNA. Because of their central role in supporting malignant growth, both Pol I and Pol III have emerged as attractive targets for anti-cancer therapies, particularly in tumors characterized by high rates of protein synthesis. Despite the promise of targeting ribosome biogenesis, current therapeutic approaches are limited by their specificity; most available inhibitors are designed to act on either Pol I or Pol III, but not both. This single-target strategy presents a significant drawback: cancer cells can adapt by compensating with the uninhibited polymerase, thereby maintaining ribosome production and undermining the efficacy of the treatment. Additionally, the redundancy between Pol I and Pol III activity can contribute to the development of drug resistance, as tumor cells exploit alternative pathways to sustain their growth. These limitations highlight a critical need for more comprehensive strategies that can simultaneously disrupt both arms of ribosome biogenesis, thereby closing off compensatory mechanisms and improving therapeutic outcomes.Technology Overview:  
A rationally designed peptide inhibitor has been developed to simultaneously target RNA Polymerase I (Pol I) and RNA Polymerase III (Pol III), two enzymes essential for ribosome biogenesis in cancer cells. This peptide works by disrupting the POLR1D/POLR1C heterodimer, a shared subunit interface crucial for the assembly and function of both polymerase complexes. By interfering with this common component, the peptide effectively suppresses the transcriptional activity of Pol I, which synthesizes ribosomal RNAs, and Pol III, which produces transfer RNAs—both necessary for protein synthesis and rapid cell proliferation. This technology is differentiated by its dual-targeting mechanism, which addresses a significant limitation of current therapies that inhibit either Pol I or Pol III alone. Single-polymerase inhibitors can be circumvented by cancer cells through compensatory upregulation of the uninhibited polymerase, reducing treatment efficacy and fostering drug resistance. By simultaneously shutting down both Pol I and Pol III, this peptide inhibitor provides a more comprehensive blockade of ribosome production, directly attacking a critical vulnerability in cancer cell metabolism. This approach not only promises enhanced therapeutic outcomes and reduced resistance but also opens new avenues for precision oncology, diagnostics, and the development of peptide-based therapeutics for other diseases involving aberrant transcriptional regulation. https://suny.technologypublisher.com/files/sites/adobestock_327332113.jpegAdvantages:  
•    Simultaneous inhibition of RNA Polymerase I and III enhances suppression of ribosome biogenesis in cancer cells.
•    Reduces cancer proliferation by targeting a shared essential subunit interface (POLR1D/POLR1C) critical for polymerase assembly.
•    Potentially lowers drug resistance by preventing compensatory upregulation of either polymerase.
•    May reduce toxicity compared to single-target therapies through more precise dual inhibition.
•    Applicable as a direct anti-cancer therapeutic and as a diagnostic tool for tumors with high Pol I/III activity.
•    Provides a versatile peptide scaffold adaptable for other protein-protein interaction targets and drug delivery systems.
•    Serves as a research tool for synthetic biology and gene expression modulation.
•    Offers a platform for developing anti-microbial and anti-fungal agents targeting analogous polymerases in pathogens. Applications:  
•    Cancer therapeutics
•    Precision oncology diagnostics
•    Peptide drug development platforms
•    Synthetic biology research tools Intellectual Property Summary:
Patent application 63/779,861 filed on 3/28/2025Stage of Development:
TRL 2Licensing Status:
This technology is available for licensing.